Crizotinib hard capsules 200 mg and 250 mg product-specific bioequivalence guidance

  • Email
  • Help
Current version

Adopted guideline

Reference numberEMA/CHMP/805479/2016
Published10/07/2017
Effective from01/01/2018
KeywordsBioequivalence, generics, crizotinib
DescriptionThis document provides product-specific guidance on the demonstration of the bioequivalence of crizotinib.
Abbreviations
  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
  • Cmax: maximum plasma concentration


Document history

Current version

Adopted guideline
 
 

Draft guideline

Published: 10/07/2017
Effective from: 01/01/2018
 

Published: 22/12/2016

Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more